CN110314236A - 聚乙二醇与雷帕霉素的结合物及其用途 - Google Patents
聚乙二醇与雷帕霉素的结合物及其用途 Download PDFInfo
- Publication number
- CN110314236A CN110314236A CN201910241970.3A CN201910241970A CN110314236A CN 110314236 A CN110314236 A CN 110314236A CN 201910241970 A CN201910241970 A CN 201910241970A CN 110314236 A CN110314236 A CN 110314236A
- Authority
- CN
- China
- Prior art keywords
- factor
- disease
- enzyme
- purposes
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 42
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 40
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 40
- 229920001223 polyethylene glycol Polymers 0.000 title claims description 63
- 239000002202 Polyethylene glycol Substances 0.000 title claims description 25
- 239000003814 drug Substances 0.000 claims abstract description 48
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 230000028993 immune response Effects 0.000 claims abstract description 22
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 230000001900 immune effect Effects 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims description 38
- 108090000790 Enzymes Proteins 0.000 claims description 38
- 229940088598 enzyme Drugs 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- -1 factors IX Proteins 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 208000030159 metabolic disease Diseases 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 15
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000003827 glycol group Chemical group 0.000 claims description 12
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 11
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 11
- 230000006798 recombination Effects 0.000 claims description 11
- 238000005215 recombination Methods 0.000 claims description 11
- 229960000182 blood factors Drugs 0.000 claims description 10
- 208000016097 disease of metabolism Diseases 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 102000015636 Oligopeptides Human genes 0.000 claims description 9
- 108010038807 Oligopeptides Proteins 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000003114 blood coagulation factor Substances 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 230000006320 pegylation Effects 0.000 claims description 9
- 229940019700 blood coagulation factors Drugs 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 208000014951 hematologic disease Diseases 0.000 claims description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 108010014172 Factor V Proteins 0.000 claims description 6
- 108010074864 Factor XI Proteins 0.000 claims description 6
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 6
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 239000005864 Sulphur Substances 0.000 claims description 6
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 6
- 108010092464 Urate Oxidase Proteins 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 229960004203 carnitine Drugs 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 5
- 208000027219 Deficiency disease Diseases 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 208000031220 Hemophilia Diseases 0.000 claims description 5
- 208000009292 Hemophilia A Diseases 0.000 claims description 5
- 206010025476 Malabsorption Diseases 0.000 claims description 5
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 5
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000005515 coenzyme Substances 0.000 claims description 5
- 229960004222 factor ix Drugs 0.000 claims description 5
- 208000016361 genetic disease Diseases 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 102100037362 Fibronectin Human genes 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 102000013566 Plasminogen Human genes 0.000 claims description 4
- 108010051456 Plasminogen Proteins 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- 229960002964 adalimumab Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 235000010894 Artemisia argyi Nutrition 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 102100030563 Coagulation factor XI Human genes 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 108010074604 Epoetin Alfa Proteins 0.000 claims description 3
- 108010014173 Factor X Proteins 0.000 claims description 3
- 108010074860 Factor Xa Proteins 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 208000027472 Galactosemias Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 108010056771 Glucosidases Proteins 0.000 claims description 3
- 102000004366 Glucosidases Human genes 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 108090000481 Heparin Cofactor II Proteins 0.000 claims description 3
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 3
- 102100035792 Kininogen-1 Human genes 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims description 3
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims description 3
- 208000033868 Lysosomal disease Diseases 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 108090000113 Plasma Kallikrein Proteins 0.000 claims description 3
- 208000016855 Porphyrin metabolism disease Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 229940096437 Protein S Drugs 0.000 claims description 3
- 108010066124 Protein S Proteins 0.000 claims description 3
- 102000029301 Protein S Human genes 0.000 claims description 3
- 108010094028 Prothrombin Proteins 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
- 229940022705 aldurazyme Drugs 0.000 claims description 3
- 244000030166 artemisia Species 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 108010089934 carbohydrase Proteins 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 239000000701 coagulant Substances 0.000 claims description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 229940012882 elaprase Drugs 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229960003388 epoetin alfa Drugs 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 201000004541 glycogen storage disease I Diseases 0.000 claims description 3
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 102000057593 human F8 Human genes 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 208000026621 hypolipoproteinemia Diseases 0.000 claims description 3
- 108010072166 idursulfase Proteins 0.000 claims description 3
- 229960002127 imiglucerase Drugs 0.000 claims description 3
- 108010039650 imiglucerase Proteins 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 210000003712 lysosome Anatomy 0.000 claims description 3
- 230000001868 lysosomic effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 150000004032 porphyrins Chemical class 0.000 claims description 3
- 229940047431 recombinate Drugs 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 229960005356 urokinase Drugs 0.000 claims description 3
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 3
- 102100036537 von Willebrand factor Human genes 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108090000935 Antithrombin III Proteins 0.000 claims description 2
- 102000004411 Antithrombin III Human genes 0.000 claims description 2
- 102000009133 Arylsulfatases Human genes 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 2
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims description 2
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims description 2
- 229960005348 antithrombin iii Drugs 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 108060007951 sulfatase Proteins 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 3
- 108010071289 Factor XIII Proteins 0.000 claims 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 2
- 108010000499 Thromboplastin Proteins 0.000 claims 2
- 102000002262 Thromboplastin Human genes 0.000 claims 2
- 229940012444 factor xiii Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 claims 1
- 102000057234 Acyl transferases Human genes 0.000 claims 1
- 108700016155 Acyl transferases Proteins 0.000 claims 1
- 208000029751 Amino acid metabolism disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102000010911 Enzyme Precursors Human genes 0.000 claims 1
- 108010062466 Enzyme Precursors Proteins 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims 1
- 229940082620 antifibrinolytics Drugs 0.000 claims 1
- POIARNZEYGURDG-FNORWQNLSA-N beta-damascenone Chemical compound C\C=C\C(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-FNORWQNLSA-N 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 108060003552 hemocyanin Proteins 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 206010052779 Transplant rejections Diseases 0.000 abstract description 2
- 230000001363 autoimmune Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000011049 pearl Substances 0.000 description 31
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 23
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 239000002023 wood Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229960000575 trastuzumab Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 150000002772 monosaccharides Chemical class 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002539 nanocarrier Substances 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960001743 golimumab Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229960000598 infliximab Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960005267 tositumomab Drugs 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100031939 Erythropoietin Human genes 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 229960002806 daclizumab Drugs 0.000 description 3
- 238000002242 deionisation method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 229950010245 ibalizumab Drugs 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229960002087 pertuzumab Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960003824 ustekinumab Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 3
- 229950009819 zotarolimus Drugs 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 2
- 206010001939 Aminoaciduria Diseases 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 208000009796 Gangliosidoses Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010053250 Glycogen storage disease type III Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000010557 Lipid storage disease Diseases 0.000 description 2
- 208000000501 Lipidoses Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010068701 Pegloticase Proteins 0.000 description 2
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 2
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000010346 Sphingolipidoses Diseases 0.000 description 2
- 201000001307 Sphingolipidosis Diseases 0.000 description 2
- 208000005350 Sulfatidosis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 2
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229960003227 afelimomab Drugs 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229950006061 anatumomab mafenatox Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229950005725 arcitumomab Drugs 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 239000012237 artificial material Substances 0.000 description 2
- 229950000103 atorolimumab Drugs 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 229950003269 bectumomab Drugs 0.000 description 2
- 229960003270 belimumab Drugs 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229950001303 biciromab Drugs 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 229940034605 capromab pendetide Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 229960000419 catumaxomab Drugs 0.000 description 2
- 229950006754 cedelizumab Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 229950002334 clenoliximab Drugs 0.000 description 2
- 229950007409 dacetuzumab Drugs 0.000 description 2
- 229950008962 detumomab Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229950005168 dorlimomab aritox Drugs 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 229950011109 edobacomab Drugs 0.000 description 2
- 229960001776 edrecolomab Drugs 0.000 description 2
- 229960000284 efalizumab Drugs 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 229950000565 enlimomab pegol Drugs 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229950001488 faralimomab Drugs 0.000 description 2
- 229950001563 felvizumab Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229950001109 galiximab Drugs 0.000 description 2
- 201000006440 gangliosidosis Diseases 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229950002200 igovomab Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229950007354 imciromab Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000015978 inherited metabolic disease Diseases 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229950007937 inolimomab Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 229940120535 krystexxa Drugs 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229950010470 lerdelimumab Drugs 0.000 description 2
- 229950002950 lintuzumab Drugs 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229950008083 maslimomab Drugs 0.000 description 2
- 229950008001 matuzumab Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 229960005108 mepolizumab Drugs 0.000 description 2
- 229950002142 minretumomab Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 229950003063 mitumomab Drugs 0.000 description 2
- 229950008897 morolimumab Drugs 0.000 description 2
- 229960003816 muromonab-cd3 Drugs 0.000 description 2
- 229950003027 nacolomab tafenatox Drugs 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 229960002915 nebacumab Drugs 0.000 description 2
- 229950009675 nerelimomab Drugs 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229950010203 nimotuzumab Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229950005751 ocrelizumab Drugs 0.000 description 2
- 229950010465 odulimomab Drugs 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229950007318 ozogamicin Drugs 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 229950003700 priliximab Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229950005854 regavirumab Drugs 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229950009092 rovelizumab Drugs 0.000 description 2
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 2
- 229950007308 satumomab Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229950004951 sevirumab Drugs 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 229950008684 sibrotuzumab Drugs 0.000 description 2
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 229950002549 stamulumab Drugs 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229950010708 sulesomab Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229950004218 talizumab Drugs 0.000 description 2
- 229950000864 technetium (99mtc) nofetumomab merpentan Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 229950005082 tuvirumab Drugs 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229950005208 vepalimomab Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229950001346 zolimomab aritox Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- FOIAQXXUVRINCI-LBAQZLPGSA-N (2S)-2-amino-6-[[4-[2-[bis(carboxymethyl)amino]-3-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propyl]phenyl]carbamothioylamino]hexanoic acid Chemical compound N[C@@H](CCCCNC(=S)Nc1ccc(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)cc1)C(O)=O FOIAQXXUVRINCI-LBAQZLPGSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 102100035970 Growth/differentiation factor 9 Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001075110 Homo sapiens Growth/differentiation factor 9 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000642464 Homo sapiens Spermatogenesis-associated protein 2-like protein Proteins 0.000 description 1
- 241000700195 Hydrochoerus hydrochaeris Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 101800003845 Neuropeptide Y Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102000009087 Prolactin-Releasing Hormone Human genes 0.000 description 1
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 101150014221 Son gene Proteins 0.000 description 1
- 102100030254 Spermatogenesis-associated protein 2 Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000282443 Ursidae Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229950008459 alacizumab pegol Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 208000022877 amino acid metabolic disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- 229950010559 besilesomab Drugs 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229950001357 celmoleukin Drugs 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229950010905 citatuzumab bogatox Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229950002595 clivatuzumab tetraxetan Drugs 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 229950002507 elsilimomab Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229950001757 epitumomab Drugs 0.000 description 1
- 229950006414 epitumomab cituxetan Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 229940093443 fanolesomab Drugs 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950011078 foravirumab Drugs 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 229950004792 gavilimomab Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229940126613 gomiliximab Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229950010828 keliximab Drugs 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 229950001275 lemalesomab Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 229940091827 lumizyme Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950009793 naptumomab estafenatox Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950009057 oportuzumab monatox Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000002877 prolactin releasing hormone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 229950001603 taplitumomab paptox Drugs 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229950008300 telimomab aritox Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 108010050939 thrombocytin Proteins 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 229950000386 vapaliximab Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229950009083 ziralimumab Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种PEG与雷帕霉素的结合物及其用途,特别是在制备用于减少免疫应答的药物中的用途,其中所述PEG与雷帕霉素的结合物可显著降低针对外源免疫原的抗体生产率,减少因其施用而引起的过强的免疫应答,具有可保证甚至改善治疗剂的治疗效果、改善接受者自身免疫状况、降低甚至消除移植排斥反应等有益效果,且其制备工艺相对简单,成本较低,易实现工业化生产,有非常好的应用价值。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种聚乙二醇与雷帕霉素的结合物及其用途,特别是在制备用于减少免疫应答的药物中的用途,更具体为聚乙二醇与雷帕霉素的结合物在制备用于减少接受者对外源免疫原如治疗剂、移植物等引起的过强的免疫应答的药物中的用途。
背景技术
免疫原性,是指能够刺激机体形成特异抗体或致敏淋巴细胞的能力,即指抗原能刺激特定的免疫细胞,使免疫细胞活化、增殖、分化,最终产生免疫效应物质抗体和致敏淋巴细胞的特性。免疫应答是指机体免疫系统对免疫原刺激所产生的以排除抗原为目的的生理过程。
一些治疗剂基于其自身的化学特性,也具有免疫原性,如某些大分子蛋白质和多糖、小分子多肽和核酸等,及移植物如细胞、组织、器官、人工材料等,也可能诱导产生免疫应答。在这种情况下,免疫系统中的细胞识别该治疗剂、移植物,并发起攻击、破坏和清除的免疫学反应,不利于患者的治疗,给患者带来更多的痛苦,甚至可能加重病情危及生命。
雷帕霉素(又名西罗莫司)是1975年在智利复活节岛的土壤中发现的由吸水链霉菌产生的一种大环内酯类抗生素,其作为免疫抑制剂,在1989年被美国Home Products公司研制开发作为抗移植排异反应的新药进入临床,并于1999年9月通过美国FDA批准上市。虽然雷帕霉素在临床上表现出良好的前景,但仍存在生物利用度低、水溶性差等缺陷。近年来,一些研究人员通过雷帕霉素与纳米载体结合用于降低上述过强的免疫应答,如专利申请CN201480031937.3中公开了未与合成纳米载体连接的治疗性大分子和与合成纳米载体连接的免疫抑制剂的给药组合,用于降低不期望的体液免疫应答。
但上述雷帕霉素与纳米载体的结合物制备工艺复杂,成本较高,纳米载体粒径分布较宽,产品批次稳定性较差,治疗效果不理想,不利于工业化放大生产和实际应用。
发明内容
为克服现有技术的不足,本发明提供一种聚乙二醇与雷帕霉素的结合物在制备用于减少免疫应答的药物中的用途,所述聚乙二醇与雷帕霉素的结合物具有通式Ⅰ所示结构:
PEG-X-D
(Ⅰ)
其中,
PEG为聚乙二醇残基,
D为雷帕霉素或其衍生物残基,
X为PEG和D之间的连接基团。
优选地,所述结合物中,所述X选自:-(CR1R2)a-、-(CH2)aNH-、-(CH2)aNHCO-、 -(CH2)aCONH-、-(CH2)aCO-、-(CH2)aCOO-、-(CH2)aO-、环烷基、芳基、杂环基、-A-和-Op- 中的一种或多种的组合,
其中,a为0-10的整数,
R1和R2独立地选自:-H、C1-6的烷基、-OR'、-NHR'、-N(R')2、-CN、-F、-Cl、-Br、-I、-COR'、-COOR'、-OCOR'、-CONHR'和-CON(R')2中的一种或两种以上的组合,
R'选自:-H、C1-6的烷基、-F、-Cl、-Br和-I,
-A-为氨基酸残基,
-Op-为寡肽残基(如含2-10(具体如2、3、4、5、6、7、8、9或10)个氨基酸残基的多肽)。
在本发明的一个实施方式中,所述X具有如下结构:-X1-X2-X3-,其中,X1和X3独立地选自:-(CR1R2)a-、-(CH2)aNH-、-(CH2)aNHCO-、-(CH2)aCONH-、-(CH2)aCO-、-(CH2)aCOO- 和-(CH2)aO-中的一种或多种的组合,X2选自:环烷基、芳基、杂环基、-A-和-Op-。
优选地,所述氨基酸残基-A-选自如下所示结构: 中的一种,
其中,G选自:-H、-CH3、 -CH2-S-CH3、 -CH2OH、-CH2SH、-CH2CONH2、-CH2CH2CONH2、 优选自:-H、-CH3、 更优选地,G为-H或-CH3。
优选地,所述寡肽残基-Op-含有2-10个氨基酸残基,所述氨基酸残基相同或不同,选自本发明上述氨基酸残基-A-的限定方案;所述寡肽残基-Op-可为直链状寡肽残基,如甘氨酸的二肽三肽等,此时所述寡肽残基-Op-有两个可连接位点;所述寡肽残基-Op-也可为分支状寡肽残基,如(m为1、2、3或4),其中A1选自:天冬氨酸、谷氨酸、赖氨酸的残基, A2和A3相同或不同,选自本发明上述氨基酸残基-A-的限定方案,具体如中国专利申请CN201410715522.X中所述的多爪寡肽,特别如
R1和R2独立地选自:-H、C1-6的烷基、-OR'、-NHR'、-N(R')2、-CN、-F、-Cl、-Br、 -I、-COR'、-COOR'、-OCOR'、-CONHR'和-CON(R')2中的一种或两种以上的组合,R'选自: -H、C1-6的烷基、-F、-Cl、-Br和-I,
a为0-10的整数。
优选地,所述R'选自:-H和C1-3的烷基(如甲基、乙基、正丙基或异丙基)。
优选地,所述R1和R2独立地选自:H、C1-3的烷基(如甲基、乙基、正丙基或异丙基)、-OH、C1-3的烷氧基(即-OR',R'为C1-3的烷基)、-NH2、-F、-Cl、-Br和-I中的一种或多种的组合;更优选自:H、-CH3、-OH、-OCH3和-OCH2CH3。
优选地,所述a为0-5的整数,如0、1、2、3、4或5。
优选地,所述X1和X3独立选自:单键、-CH2-、-CH2CH2-、-CH2CH2CH2-、-CH2CO-、 -CH2CH2CO-、-CH2NH-、-CH2NHCH2-、-CH2CONH-、-CH2CONHCH2-、-CH2NHCO-、 --CH2NHCOCH2-、-CH2COO-、-CH2COOCH2-、-CH2O-、-CH2OCH2-中的一种或多种的组合。
在本发明的一个实施例中,所述X1为-CH2CO-。
在本发明的另一个实施例中,所述X1为-CH2OCH2-。
在本发明的另一个实施例中,所述X1为-CH2CONHCH2-。
在本发明的一个实施例中,所述X3为单键。
在本发明的一个实施例中,所述X3为-CH2CO-。
在本发明的一个实施方式中,所述-Op-具有如下结构:
其中,m为1、2、3或4,
A1选自:天冬氨酸、谷氨酸、赖氨酸的残基,
A2和A3相同或不同,独立地选自如下结构:其中G具有本发明上述定义。
在本发明的一个实施例中,所述A1为谷氨酸残基
在本发明的一个实施例中,所述A2和A3相同,均为甘氨酸残基
在本发明的一个具体实施方式中,所述-Op-具有如下结构:优选地,m为2或3。本发明通式Ⅰ所示结合物中,所述连接基团X可以仅含有两个连接位点,分别连接PEG和D;所述X也可含有三个以上连接位点,连接一个聚乙二醇残基和两个以上雷帕霉素或其衍生物残基,达到提高药物负载量等目的,也可连接一个雷帕霉素或其衍生物残基和两个以上聚乙二醇残基,达到提高结合物水溶性或空间位阻等目的。
在本发明另一个实施方式中,所述X为-X1-Op-X3-,-Op-具有本发明上述定义。
在本发明的一个实施例中,所述X为优选地, m为2或3。
优选地,所述结合物中,所述PEG为直链、Y型、多分支的聚乙二醇残基,例如包括单甲氧基聚乙二醇(mPEG)、直链双端PEG、Y型PEG、4臂支链PEG、6臂支链PEG 或8臂支链PEG等。
优选地,所述的PEG的分子量可为1-100KDa,例如1-10KDa(具体可为1、2、3、4、 5、6、7、8、9或10KDa)、10-50KDa(具体可为10、15、20、25、30、35、40、45或 50KDa)或50-100KDa(具体可为50、55、60、65、70、75、80、85、90、95或100KDa) 等;进一步优选为10-50KDa。
在本发明一具体实施方式中,所述PEG为直链聚乙二醇残基,具有通式Ⅱ或Ⅲ所示的结构:
其中,p和q独立地选自1-2280的整数,优选为220-1140的整数,
Y为端基,具有-L-T结构,
其中,L为氧(O)和封端基T之间的连接基团,选自:-(CH2)b-、-(CR3R4)b-、-(CH2)bNH-、 -(CH2)bNHCO-、-(CH2)bCONH-、-(CH2)bCO-、-(CH2)bCOO-和-(CH2)bO-中的一种或多种的组合,其中b为0-10的整数,
R3和R4独立地选自:-H、C1-6的烷基、-OR”、-NHR”、-N(R”)2、-CN、-F、-Cl、-Br、 -I、-COR”、-COOR”、-OCOR”、-CONHR”和-CON(R”)2中的一种或多种的组合,
R”选自:-H、C1-6的烷基、-F、-Cl、-Br和-I,
T为封端基,选自:H、C1-6的烷基、C3-6的环烷基、C4-10的环烷基烷基、C6-10 的芳基、C7-14的芳烷基、单糖和低聚糖残基。
优选地,所述L选自:单键、-CH2-、-CH2CH2-、-CH2CH2CH2-、-CONH-、-NH-、-CO-、 -CONHCH2-、-CH2NH-、-CH2CONH-和-COCH2-中的一种或多种的组合。
优选地,所述T选自:甲基、乙基、异丙基、环丙基、环丙基甲基、环丁基、环己基、苄基、
优选地,所述Y选自:甲基、乙基、异丙基、环丙基、环丙基甲基、环丁基、环己基、苄基、
在本发明的一个优选实施例中,所述Y为甲基。
在本发明的另一个优选实施例中,所述Y为
在本发明一具体实施方式中,所述PEG为Y型聚乙二醇残基,具有通式Ⅳ或Ⅴ所示的结构:
其中,i和h独立地选自1-1140的整数,优选为110-570的整数,
Y具有本发明上述通式Ⅱ中定义的结构,优选自:甲基、乙基、异丙基、环丙基、环丙基甲基、环丁基、环己基、苄基、更优选自:甲基、
在本发明一具体实施方式中,所述PEG为多分支聚乙二醇残基,具有通式Ⅵ所示的结构:
其中,k是1-760的整数,优选为70-380的整数,
j是3-8的整数,
R是多分支聚乙二醇的核心分子,R选自:季戊四醇、寡聚季戊四醇、甲基葡萄糖苷、蔗糖、二甘醇、丙二醇、甘油和聚甘油的残基。
优选地,R选自:季戊四醇、寡聚季戊四醇、甘油和聚甘油的残基;更优选自:季戊四醇、二聚季戊四醇、三聚季戊四醇、甘油和六聚甘油残基。
在本发明的一个实施例中,所述多分支聚乙二醇残基仅含有一个可连接位点,其具有如下结构:
其中,Y具有本发明上述通式Ⅱ中定义的结构,优选自:甲基、乙基、异丙基、环丙基、环丙基甲基、环丁基、环己基、苄基、更优选自:甲基、
在本发明一个优选实施例中,所述多分支聚乙二醇残基具有如下结构:
其中,k是1-570的整数,优选为55-285的整数,
x为1-10的整数(具体如1、2、3、4、5、6、7、8、9或10),优选为1-6的整数,
其中,Y具有本发明上述通式Ⅱ中定义的结构,优选自:甲基、乙基、异丙基、环丙基、环丙基甲基、环丁基、环己基、苄基、更优选自:甲基、
在本发明另一个优选实施例中,所述多分支聚乙二醇残基具有如下结构:
其中,k是1-280的整数,优选为28-140的整数,
y为1-10的整数(具体如1、2、3、4、5、6、7、8、9或10),优选为1-5的整数,更优选为1-3的整数,
Y具有本发明上述通式Ⅱ中定义的结构,优选自:甲基、乙基、异丙基、环丙基、环丙基甲基、环丁基、环己基、苄基、更优选自:甲基、
在本发明中,当所述PEG具有上述通式Ⅱ、Ⅳ或Ⅴ的结构时,一个PEG分子可通过其连接位点通过连接基团X与药物D结合;当所述PEG具有上述通式Ⅲ或Ⅵ的结构时,一个PEG分子具有两个以上可连接位点,PEG可通过其中一个连接位点通过连接基团X与药物D结合,此时,所述结合物中只含有一个药物残基,PEG也可通过多个连接位点通过连接基团X与药物D结合,此时,结合物中有两个以上药物残基。优选地,所述PEG为通式Ⅲ或Ⅵ所示的具有两个以上可连接位点的PEG时,其通过一个连接位点通过连接基团 X与药物D结合,其他可连接位点可连接封端基Y(如甲基),如通式Ⅶ所示结构。
优选地,所述结合物中,所述D具有如下结构:
其中,
R5选自:H、C1-C6的烷基、C2-C6的烯基、C6-C12的芳基和C7-C14的芳烷基;
R6选自:H、羟基和C1-C6的烷氧基;
R7选自:H、C1-C6的烷基、C2-C6的烯基、C6-C12的芳基、C7-C14的芳烷基和 -C(O)R71,其中R71选自:H、C1-C6的烷基、C2-C6的烯基、C6-C12的芳基和C7-C14的芳烷基;
R8选自:H、羟基和C1-C6的烷氧基;
R9选自:-O-、-O-R51-O-、其中R91为C1-C6的亚烷基;
Z为H或羟基保护基团。
优选地,式Ⅷ中,所述R5为H或C1-C6的烷基,更优选为H、甲基或乙基;在本发明的一个实施例中,所述R5为甲基。
优选地,式Ⅷ中,所述R6选自H、羟基和C1-C3的烷氧基,更优选为-OCH3、 -OCH2CH3、-O(CH2)2CH3;在本发明的一个实施例中,所述R6为甲氧基。
优选地,式Ⅷ中,所述R7选自:H、C1-C6的直链烷基、C2-C10的直链烯基、苯基、卤代苯基、苯甲基、苯乙基、-C(O)R71,其中R71选自:H、C1-C6的直链烷基,更优选为H、 -OCH3、-OCH2CH3、-O(CH2)2CH3;在本发明的一个实施例中,所述R7为H。
优选地,式Ⅷ中,所述R8选自:H、羟基和和C1-C3的烷氧基,更优选为-OCH3、 -OCH2CH3、-O(CH2)2CH3;在本发明的一个实施例中,所述R8为甲氧基。
优选地,所述R91为C1-C3的亚烷基,如-CH2-、-CH2CH2-、-CH2CH2CH2-。
在本发明的一个优选实施例中,所述式Ⅷ中,所述R5为甲基,R6为甲氧基,R7为H,R8为甲氧基。
优选地,所述结合物中,所述D选自:雷帕霉素、依维莫司、坦西莫司、比奥莫司 A9、ABT-578和地磷莫司中的一种的残基。
更优选地,所述结合物中,所述D选自: 中的一种,
其中,Z为H或羟基保护基团。
此处所述羟基保护基团,本领域技术人员在本发明的基础上可根据实际情况选择本领域常用的羟基保护基团,如-CH3、-C(CH3)3、-CH2OCH3、-COCH3、-COC(CH3)3、 -CH2CH=CH2、-Si(CH3)3、等,本发明对此不做具体限定。
在本发明的一个优选实施例中,所述结合物中,所述D具有如下结构:
在本发明的一个具体实施方式中,所述结合物具有如下结构:
上式中,PEG、m、D具有本发明上述定义。
优选地,式Ⅸ中,所述PEG具有本发明上述通式Ⅱ的结构;更优选地,所述PEG具有如下结构:p具有本发明上述定义。
优选地,式Ⅸ中,所述PEG的分子量为10-50KDa,更优选为20KDa。
优选地,式Ⅸ中,所述m为2或3。
优选地,式Ⅸ中,所述D具有如下结构:
在本发明的一方面,所述的免疫应答是由外源免疫原引起的,优选地,所述用途为聚乙二醇与雷帕霉素的结合物在制备用于减少接受者对外源免疫原的过强的免疫应答的药物中的用途。
优选地,所述接受者为哺乳动物,优选为灵长目动物,更优选为人。
优选地,所述的外源免疫原选自:治疗剂、移植物、人工抗原载体、毒素等。
在本发明的一个实施方式中,所述外源免疫原为治疗剂;优选地,所述治疗剂为治疗性大分子,更优选为治疗性蛋白质,如细胞因子、人血红蛋白、血液因子或凝血因子、血管内皮生长因子抗体拮抗剂、激素、抗体、酶及辅酶;更优选地,所述治疗性蛋白质为抗体或酶及辅酶。
本发明中,所述细胞因子的实例包括但不限于:白细胞介素、集落刺激因子、干扰素、生长因子、肿瘤坏死因子、转化生长因子-β家族或趋化因子家族等。
本发明中,所述生长因子的实例包括但不限于:肾上腺髓质素(AM)、血管生成素(Ang)、自分泌运动因子、骨形态生成蛋白(BMP)、脑源性神经营养因子(BDNF)、表皮生长因子 (EGF)、红细胞生成素(EPO)、成纤维细胞生长因子(FFGF)、神经胶质细胞系源性神经营养因子(GDNF)、粒细胞集落刺激因子(G-CSF)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、生长分化因子-9(GDF9)、肝细胞生长因子(HGF)、肝癌源性生长因子(HDGF)、胰岛素样生长因子(IGF)、促移行因子、肌生长抑制素(GDF-8)、神经生长因子(NGF)及其他神经营养因子、血小板源性生长因子(PDGF)、血小板生成素(TPO)、转化生长因子α(TGF-α)、转化生长因子β(TGF-β)、肿瘤坏死因子α(TNF-α)、血管内皮生长因子(VEGF)、Wnt信号传导途径、胎盘生长因子P1GF)、IL-1、IL-2、IL-3、IL-4、IL-5、IL-6和IL-7。
本发明中,所述血液因子或凝血因子的实例包括但不限于:因子I、因子II、组织因子、因子V、因子VII(例如长效凝血因子VII)、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、重组凝血因子(例如重组凝血因子VIII)、冯·维勒布兰德因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤溶酶、组织纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌促凝物质或阿法依伯汀等。
在本发明的一个实施例中,所述血液因子或凝血因子为因子VIII。
本发明中,所述激素包括但不限于:褪黑激素(N-乙酰基-5-甲氧基色胺)、血清素、甲状腺素(或四碘甲腺原氨酸)(甲状腺激素)、三碘甲腺氨酸(甲状腺激素)、肾上腺素(或肾上腺激素)、去甲肾上腺素(或去甲肾上腺激素)、多巴胺(或催乳素抑制激素)、抗米勒管激素(或米勒管抑制因子或激素)、脂连蛋白、促肾上腺皮质激素(或促皮质素)、血管紧张素原和血管紧张素、抗利尿激素(或加压素、精氨酸加压素)、心房钠尿肽(或心钠素)、降钙素、胆囊收缩素、促皮质素释放激素、红细胞生成素、促卵泡激素、胃泌素、生长素释放肽、胰高血糖素、胰高血糖素样肽(GLP-1)、GIP、促性腺素释放激素、生长激素释放激素、人绒毛膜促性腺素、人胎盘催乳素、生长激素、抑制素、胰岛素、胰岛素样生长因子(或生长调节素)、瘦素、黄体化激素、黑素细胞刺激激素、食欲素、催产素、甲状旁腺激素、催乳素、松弛素、分泌素、生长激素抑制素、血小板生成素、甲状腺刺激激素(或促甲状腺素)、促甲状腺素释放激素、皮质醇、醛固酮、睾酮、去氢表雄酮、雄烯二酮、二氢睾酮、雌二醇、雌酮、雌三醇、黄体酮、骨化三醇(1,25-二羟基维生素D3)、骨化二醇(25-羟基维生素D3)、前列腺素类、白三烯类、前列环素、血栓烷类、催乳素释放激素、促脂解素、脑钠尿肽、神经肽Y、组胺、内皮素、胰多肽、肾素和脑啡肽等。
本发明中,所述抗体包括:单克隆抗体、多克隆抗体、二聚体、多聚体、双特异性抗体、多特异性抗体和抗体片段(例如Fab、Fab'、F(ab)2、F(ab')2和Fv等)等;所述单克隆抗体的实例具体如阿达木单抗(Adalimumab,HUMIRA)、托珠单抗(Tocilizumab)、奥瑞珠单抗(Ocrelizumab)、贝利木单抗(Belimumab)、英利昔单抗(Infliximab)、利妥昔单抗(Rituximab)、曲妥珠单抗(Trastuzumab)、贝伐珠单抗(Bevacizumab)、阿伦珠单抗(Alemtuzumab)、西妥昔单抗(Cetuximab)、帕尼单抗(Panitumumab)、尼妥珠单抗(Nimotuzumab)、帕妥珠单抗(Pertuzumab)、替依莫单抗(Ibritumomab)、托西莫单抗(Tositumomab)、奥马珠单抗(Omalizumab)、阿巴伏单抗(Abagovomab)、阿昔单抗(Abciximab)、阿德木单抗(Adecatumumab)、阿非莫单抗(Afelimomab)、阿夫土珠单抗(Afutuzumab)、培化阿珠单抗(Alacizumab pegol)、喷替酸阿妥莫单抗(Altumomabpentetate)、麻安莫单抗(Anatumomabmafenatox)、安芦珠单抗(Anrukinzumab)(IMA-638)、阿泊珠单抗(Apolizumab)、阿西莫单抗(Arcitumomab)、阿塞珠单抗(Aselizumab)、阿托木单抗(Atorolimumab)、巴匹珠单抗(Bapineuzumab)、巴利昔单抗(Basiliximab)、巴土昔单抗(Bavituximab)、贝妥莫单抗(Bectumomab)、贝利木单抗(Belimumab)、柏替莫单抗(Bertilimumab)、贝索单抗(Besilesomab)、贝伐单抗(Bevacizumab)、比西单抗(Biciromab)、比伐单抗-DM1(Bivatuzumabmertansine)、兰妥莫单抗(Blinatumomab)、本妥昔单抗(Brentuximabvedotin)、ABT-874(Briakinumab)、卡那单抗(Canakinumab)、美坎珠单抗(Cantuzumabmertansine)、卡罗单抗喷地肽(Capromabpendetide)、卡妥索单抗 (Catumaxomab)、西利珠单抗(Cedelizumab)、培舍珠单抗(Certolizumabpegol)、泊西他珠单抗(Citatuzumabbogatox)、西妥木单抗(Cixutumumab)、克立昔单抗(Clenoliximab)、Clivatuzumabtetraxetan、CNTO148(戈利木单抗(golimumab))、CNTO1275(优特克单抗 (ustekinumab))、可那木单抗(Conatumumab)、达西珠单抗(Dacetuzumab)、达克珠单抗 (Daclizumab)、地舒单抗(Denosumab)、地莫单抗(Detumomab)、阿托度单抗 (Dorlimomabaritox)、Dorlixizumab、依美昔单抗(Ecromeximab)、依库珠单抗(Eculizumab)、埃巴单抗(Edobacomab)、依决洛单抗(Edrecolomab)、依法珠单抗(Efalizumab)、依夫单抗 (Efungumab)、艾西莫单抗(Elsilimomab)、培戈赖莫单抗(Enlimomabpegol)、西依匹莫单抗(Epitumomabcituxetan)、依帕珠单抗(Epratuzumab)、厄利珠单抗(Erlizumab)、厄马索单抗 (Ertumaxomab)、埃达珠单抗(Etaracizumab)、艾韦单抗(Exbivirumab)、法索单抗(Fanolesomab)、法拉莫单抗(Faralimomab)、非维珠单抗(Felvizumab)、非扎奴单抗(Fezakinumab)、芬妥木单抗(Figitumumab)、芳妥珠单抗(Fontolizumab)、福拉韦单抗(Foravirumab)、夫苏木单抗(Fresolimumab)、加利昔单抗(Galiximab)、Gantenerumab、加维莫单抗(Gavilimomab)、吉妥珠单抗奥佐米星(Gemtuzumabozogamicin)、戈利木单抗(Golimumab)、戈利昔单抗(Gomiliximab)、Ibalizumab、替伊莫单抗(Ibritumomabtiuxetan)、伊戈伏单抗(Igovomab)、英西单抗(Imciromab)、英利昔单抗(Infliximab)、英妥木单抗 (Intetumumab)、伊诺莫单抗(Inolimomab)、伊珠单抗奥佐米星(Inotuzumabozogamicin)、伊匹木单抗(Ipilimumab)、伊妥木单抗(Iratumumab)、凯利昔单抗(Keliximab)、拉贝珠单抗 (Labetuzumab)、来金珠单抗(Lebrikizumab)、来马索单抗(Lemalesomab)、乐地单抗 (Lerdelimumab)、来沙木单抗(Lexatumumab)、利韦单抗(Libivirumab)、林妥珠单抗 (Lintuzumab)、鲁卡木单抗(Lucatumumab)、鲁昔单抗(Lumiliximab)、马帕木单抗 (Mapatumumab)、马司莫单抗(Maslimomab)、马妥珠单抗(Matuzumab)、美泊利单抗 (Mepolizumab)、美替木单抗(Metelimumab)、米拉珠单抗(Milatuzumab)、明瑞莫单抗 (Minretumomab)、米妥莫单抗(Mitumomab)、莫罗木单抗(Morolimumab)、莫他珠单抗 (Motavizumab)、莫罗单抗-CD3(Muromonab-CD3)、MYO-029(司他莫单抗(stamulumab))、他那可单抗(Nacolomabtafenatox)、他那莫单抗(Naptumomabestafenatox)、那他珠单抗 (Natalizumab)、奈巴库单抗(Nebacumab)、奈昔木单抗(Necitumumab)、奈瑞莫单抗(Nerelimomab)、尼妥珠单抗(Nimotuzumab)、巯诺莫单抗(Nofetumomabmerpentan)、奥瑞珠单抗(Ocrelizumab)、奥度莫单抗(Odulimomab)、奥法木单抗(Ofatumumab)、莫奥珠单抗 (Oportuzumabmonatox)、奥戈伏单抗(Oregovomab)、奥昔珠单抗(Otelixizumab)、帕昔单抗 (Pagibaximab)、帕利珠单抗(Palivizumab)、帕木单抗(Panitumumab)、帕诺库单抗 (Panobacumab)、帕考珠单抗(Pascolizumab)、帕尼单抗(Pemtumomab)、培妥珠单抗 (Pertuzumab)、培克珠单抗(Pexelizumab)、平妥莫单抗(Pintumomab)、普立昔单抗(Priliximab)、普立木单抗(Pritumumab)、PRO140、雷韦单抗(Rafivirumab)、雷莫芦单抗(Ramucirumab)、雷珠单抗(Ranibizumab)、雷昔库单抗(Raxibacumab)、瑞加韦单抗(Regavirumab)、瑞利珠单抗(Reslizumab)、利妥木单抗(Rilotumumab)、罗妥木单抗(Robatumumab)、罗利珠单抗 (Rontalizumab)、罗维珠单抗(Rovelizumab)、鲁利珠单抗(Ruplizumab)、沙妥莫单抗 (Satumomab)、司韦单抗(Sevirumab)、西罗珠单抗(Sibrotuzumab)、西法木单抗(Sifalimumab)、 Siltuximab、西利珠单抗(Siplizumab)、苏兰珠单抗(Solanezumab)、ASONEP(Sonepcizumab)、松妥珠单抗(Sontuzumab)、司他芦单抗(Stamulumab)、硫索单抗(Sulesomab)、他珠单抗(Tacatuzumabtetraxetan)、他度珠单抗(Tadocizumab)、他利珠单抗(Talizumab)、他尼珠单抗 (Tanezumab)、帕他莫单抗(Taplitumomabpaptox)、替非珠单抗(Tefibazumab)、阿替莫单抗 (Telimomabaritox)、替妥莫单抗(Tenatumomab)、替奈昔单抗(Teneliximab)、替利珠单抗 (Teplizumab)、TGN1412、替西木单抗(Ticilimumab)、曲美木单抗(tremelimumab)、替加珠单抗(Tigatuzumab)、TNX-355(伊巴珠单抗(ibalizumab))、TNX-650、TNX-901(他利珠单抗 (talizumab))、托利珠单抗(Toralizumab)、托西莫单抗(Tositumomab)、曲美木单抗 (Tremelimumab)、西莫白介素单抗(Tucotuzumabcelmoleukin)、妥韦单抗(Tuvirumab)、乌珠单抗(Urtoxazumab)、优特克单抗(Ustekinumab)、伐利昔单抗(Vapaliximab)、维多珠单抗 (Vedolizumab)、维妥珠单抗(Veltuzumab)、维帕莫单抗(Vepalimomab)、维西珠单抗(Visilizumab)、伏洛昔单抗(Volociximab)、伏妥昔单抗(Votumumab)、扎芦木单抗(Zalutumumab)、扎木单抗(Zanolimumab)、齐拉木单抗(Ziralimumab)、阿佐莫单抗(Zolimomabaritox)等。
在本发明的一个实施例中,所述单克隆抗体为阿达木单抗。
本发明中,所述酶及辅酶包括但不限于:免疫酶、微生物酶、氧化还原酶、转移酶、水解酶、裂合酶、异构酶或连接酶等;具体如伊米苷酶、α-半乳糖苷酶A(α-galA)、阿加糖酶β、酸性α-葡糖苷酶(GAA)、重组阿葡糖苷酶α(LUMIZYME)、α-葡糖苷酶、芳基硫酸酯酶、拉罗尼酶、ALDURAZYME、艾杜硫酶、ELAPRASE、加硫酶(NAGLAZYME)、聚乙二醇化重组尿酸酶(KRYSTEXXA)、聚乙二醇化重组假丝酵母尿酸酶、门冬酰胺酶等。
在本发明的一个实施例中,所述酶为α-半乳糖苷酶A(α-galA)、酸性α-葡糖苷酶(GAA)、聚乙二醇化重组尿酸酶(KRYSTEXXA)、聚乙二醇化重组假丝酵母尿酸酶或门冬酰胺酶。
在本发明的另一个实施方式中,所述外源免疫原为人工抗原载体,所述的人工抗原载体是指作为载体与半抗原或其他抗原结合(如偶联)以增强其免疫原性,用于制备成人工抗原的具有免疫原性的分子,其包括如蛋白质、多肽聚合物、大分子聚合物和某些颗粒等。所述蛋白质载体(又称为载体蛋白),包括但不限于,钥孔血蓝蛋白(KLH)、牛血清蛋白(BSA)、人血清白蛋白(HSA)、卵清蛋白(OVA)等。所述的多肽聚合物载体如多聚赖氨酸(PLL)等。所述的颗粒载体如某些细菌颗粒、病毒等。
在本发明的一个具体实施方式中,所述人工抗原载体为蛋白质载体。
在本发明的一个实施例中,所述的蛋白质载体为钥孔血蓝蛋白(KLH)。
在本发明的另一个实施方式中,所述外源免疫原为移植物;优选地,所述移植物为用于移植的细胞、组织、器官或其他生物适合的移植物,所述移植物可以是自体或异体(如同物种但不同基因型个体)的细胞、组织、器官,也可为人工材料(如人工骨、人工气管等)等。
在本发明的一个具体实施方式中,所述移植物为细胞,优选为干细胞,如造血干细胞、神经干细胞等。
在本发明的一个具体实施方式中,所述移植物为组织,优选自:皮肤、骨及软骨、真皮及脂肪、黏膜、筋膜、角膜、肌肉、神经、人工生物材料等。
在本发明的一个具体实施方式中,所述移植物为器官,优选自:心脏、胰腺、肾脏、肺和肝脏等。
优选地,本发明所述用途中,所述结合物在施用外源免疫原之前、同时或之后施用。
其他示例性的治疗剂如化学治疗剂,其包括但不限于:抗代谢药物、基于铂的药剂、烷化剂、酪氨酸激酶抑制剂、蒽环类抗生物、长春花生物碱、蛋白酶体抑制剂和拓扑异构酶抑制剂等。上述治疗剂是本领域技术人员已知的,本发明在此方面不受限制。
本发明还提供了一种PEG与雷帕霉素的结合物在制备增强第一药物治疗效果的药物中的应用,所述的第一药物选自细胞因子、人血红蛋白、血液因子或凝血因子、血管内皮生长因子抗体拮抗剂、激素、抗体、酶及辅酶类药物中的至少一种。
优选地,所述的第一药物用于治疗肿瘤、血液疾病、感染性疾病、免疫系统疾病、遗传性疾病、代谢病。
更优选地,所述的肿瘤选自肺癌、肾癌、黑色素瘤、肝癌头颈癌、皮肤癌、鳞状细胞癌、卵巢癌、骨癌、结直肠癌、膀胱癌、胃癌、胰腺癌、前列腺癌、霍奇金淋巴瘤、滤泡性淋巴瘤、慢性或急性白血病、间皮瘤、胰腺癌、乳腺癌、多发性骨髓瘤和其他实体瘤;所述的血液疾病选自血友病;所述的感染性疾病选自HIV病毒感染、肝炎病毒(A型、B 型和C型)感染、疱疹病毒感染、流感病毒感染;所述免疫系统疾病选自红斑狼疮、类风湿关节炎、强直性脊柱炎、重症肌无力、多发性硬化症、自身免疫性溶血性贫血、自身免疫性肝炎、硬皮病、结节性多动脉炎、Wegener肉芽肿病;所述的血液疾病选自血友病;所述的遗传性疾病选自法布里病、庞培氏病、溶酶体积存疾病、遗传性肌肉疾病、遗传代谢疾病;所述的代谢病选自氨基酸代谢紊乱(如分支链疾病、高氨基酸血症、高氨基酸尿症)、尿素代谢紊乱、高胺血症、粘多醣病、贮积病(如肝醣贮积病及脂质贮积病)、糖原贮积病 I(如柯里氏病)、吸收不良疾病(如肠碳水化合物吸收不良)、寡醣酶缺乏症(如麦芽糖酶不足、乳糖酶不足、蔗糖酶不足)、果糖代谢障碍、半乳糖代谢障碍、半乳糖血症、碳水化合物利用紊乱(如糖尿病)、低血糖症、丙酮酸盐代谢紊乱、低脂血症、低脂蛋白血症、高脂血症、高脂蛋白血症、肉毒碱或肉毒碱酰基转移酶缺乏症、卟啉代谢紊乱、卟啉、嘌呤代谢紊乱、溶酶体病、神经及神经系统代谢疾病(如神经节苷脂沉积症、神经类脂增多症)、硫酸脑苷脂病、脑白质病、莱施-奈恩综合征。
本发明还提供了一种PEG与雷帕霉素的结合物在制备增强基因疗法效果的药物中的应用。
优选地,所述的基因疗法为非免疫原性的基因疗法,例如是采用病毒载体的非免疫原性的基因疗法。
更优选地,所述的基因疗法用于治疗癌症、血液疾病、感染性疾病、免疫系统疾病、遗传性疾病、代谢病。
进一步优选地,所述的肿瘤选自肺癌、肾癌、黑色素瘤、肝癌头颈癌、皮肤癌、鳞状细胞癌、卵巢癌、骨癌、结直肠癌、膀胱癌、胃癌、胰腺癌、前列腺癌、霍奇金淋巴瘤、滤泡性淋巴瘤、慢性或急性白血病、间皮瘤、胰腺癌、,乳腺癌、多发性骨髓瘤和其他实体瘤;所述的血液疾病选自血友病;所述的感染性疾病选自HIV病毒感染、肝炎病毒(A 型、B型和C型)感染、疱疹病毒感染、流感病毒感染;所述免疫系统疾病选自红斑狼疮、类风湿关节炎、强直性脊柱炎、重症肌无力、多发性硬化症、自身免疫性溶血性贫血、自身免疫性肝炎、硬皮病、结节性多动脉炎、Wegener肉芽肿病;所述的血液疾病选自血友病;所述的遗传性疾病选自法布里病、庞培氏病、溶酶体积存疾病、遗传性肌肉疾病、遗传代谢疾病;所述的代谢病选自氨基酸代谢紊乱(如分支链疾病、高氨基酸血症、高氨基酸尿症)、尿素代谢紊乱、高胺血症、粘多醣病、贮积病(如肝醣贮积病及脂质贮积病)、糖原贮积病I(如柯里氏病)、吸收不良疾病(如肠碳水化合物吸收不良)、寡醣酶缺乏症(如麦芽糖酶不足、乳糖酶不足、蔗糖酶不足)、果糖代谢障碍、半乳糖代谢障碍、半乳糖血症、碳水化合物利用紊乱(如糖尿病)、低血糖症、丙酮酸盐代谢紊乱、低脂血症、低脂蛋白血症、高脂血症、高脂蛋白血症、肉毒碱或肉毒碱酰基转移酶缺乏症、卟啉代谢紊乱、卟啉、嘌呤代谢紊乱、溶酶体病、神经及神经系统代谢疾病(如神经节苷脂沉积症、神经类脂增多症)、硫酸脑苷脂病、脑白质病、莱施-奈恩综合征。
本发明提供一种聚乙二醇与雷帕霉素的结合物在用于减少免疫应答中的应用。
本发明还提供了一种PEG与雷帕霉素的结合物在增强第二药物治疗效果中的应用。
本发明还提供了一种PEG与雷帕霉素的结合物在增强基因疗法效果中的应用。
本发明还提供了一种药物组合物,所述的药物组合物中包括第一药物和本发明所述的 PEG与雷帕霉素的结合物,所述的第一药物选自细胞因子、人血红蛋白、血液因子或凝血因子、血管内皮生长因子抗体拮抗剂、激素、抗体、酶及辅酶类药物中的至少一种。
本发明所述的药物或药物组合物选自片剂、丸剂、粉剂、锭剂、散剂、酏剂、悬浮液、乳液、溶液、糖浆剂、气雾剂、软膏剂、透皮吸收剂、软胶囊、硬胶囊、栓剂、无菌注射溶液以及冻干粉剂等形式。优选的,本发明所述的药物或药物组合物为无菌注射溶液或冻干粉剂。
本发明所述的药物或药物组合物中还含有药学上可接受的辅料,优选的,所述的辅料选自载体和稀释剂(乳糖、右旋糖、蔗糖、山梨醇、甘露醇、淀粉类、阿拉伯树胶、磷酸钙、藻酸盐、黄蓍胶、明胶、硅酸钙、微晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆、甲基纤维素、羟基苯甲酸甲基酯和羟基苯甲酸丙基酯、滑石、硬脂酸镁和矿物油中的一种或两种以上)、润滑剂、增溶剂、湿润剂、乳化剂和悬浮剂、防腐剂、甜味剂或矫味剂。
本发明所述的药物或药物组合物的施用方法选自口服、皮下、皮内、肌内、腹膜内、静脉内、鼻内、硬膜外、舌下、鼻内、脑内、叶鞘内、透皮、直肠等。
本发明提供了一种PEG与雷帕霉素的结合物及其用途,特别是在制备用于减少免疫应答(特别是减少接受者对外源免疫原如治疗剂、移植物等引起的过强的免疫应答)的药物中的新用途,其中所述PEG与雷帕霉素的结合物可显著降低针对外源免疫原如治疗剂、移植物的抗体生产率,减少其引起的过强的免疫应答,具有可保证甚至改善治疗剂的治疗效果、改善接受者自身免疫状况、降低甚至消除移植排斥反应等有益效果,且其制备工艺相对简单,成本较低,易实现工业化生产,有非常好的应用价值。
具体实施方式
除非另有定义,本发明中所使用的所有科学和技术术语具有与本发明涉及技术领域的技术人员通常理解的相同的含义,如:
“烷基”指的是直链或支链的且不含不饱和键的烃链自由基,C1-C6的烷基指含有1-6 个碳原子的烷基,如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、正己基等;如烷基被环烷基取代,其相应为“环烷基烷基”自由基,C4-10的环烷基烷基是指含有4-10个碳原子的环烷基烷基,如环丙基甲基、环丙基乙基、环丁基甲基、环戊基甲基、环己基甲基等;如烷基被芳基取代,那么其相应为“芳烷基”自由基,C7-14的芳烷基是指含7-14个碳原子的芳烷基,如苄基、二苯甲基或苯乙基等。
“烷氧基”指的是羟基中的氢被烷基取代后形成的取代基,C1-C6的烷氧基指含有1-6 个碳原子的烷氧基,如甲氧基、乙氧基、丙氧基、丁氧基等。
“环烷基”指的是脂环烃,如含1至4个单环和/或稠环、含3-18个碳原子,优选3-10个碳原子,如环丙基、环己基或金刚烷基等,本发明中所述“C3-6的环烷基”指含有3-6个碳原子的环烷基,如环丙基、环丁基、环戊基和环己基。
“芳基”指的是单环或多环自由基,包括含单芳基基团和/或稠芳基基团的多环自由基,如包含1-3个单环或稠环及6-18个碳环原子,本发明中所述C6-10的芳基是指含有6-10 个碳环原子的芳基,如苯基、萘基。
“杂环基”包括含1至3个单环和/或稠环及3至约18个环原子的杂芳香族基团和杂脂环基团。优选的杂芳香族基团和杂脂环基团含5至约10个环原子。本发明的化合物中的合适的杂芳基含1、2或3种杂原子,所述杂原子选自N、O或S原子,所述的含氮杂环是指其杂原子中包括N原子。
“单糖”一般是含有3-6个碳原子的多羟基醛或多羟基酮,按碳原子数目,单糖可分为丙糖、丁糖、戊糖、己糖等。常见的单糖如葡萄糖、果糖、半乳糖、核糖、脱氧核糖等。“低聚糖”是指含有2-10个糖苷键聚合而成的化合物,所述糖苷键是一个单糖的苷羟基和另一单糖的某一羟基脱水缩合形成的,常见的低聚糖如二糖、三糖等。所述“二糖”是指由两个单糖分子通过糖苷键连接在一起形成的化合物,如蔗糖、乳糖、麦芽糖等。所述“三糖”三分子单糖以糖苷键连结形成的化合物,如龙胆三糖、棉子糖等。
“雷帕霉素(rapamycin)”,也称为西罗莫司(sirolimus),本发明中雷帕霉素衍生物包括但不限于结构和功能类似于雷帕霉素的化合物,如依维莫司(everolimus,RAD 001(Novartis))、坦西莫司(temsirolimus,又称为替西罗莫司,CC1-779(Wyeth))、比奥莫司A9(biolimus A9)、ABT-578(zotarolimus)、地磷莫司(deforolimus,ridaforolimus,AP23573,MK-8669)等。上述雷帕霉素及其衍生物的化学结构如下所示:
本发明中所述“治疗剂”是指可向接受者施用并且具有治疗效果的物质,如蛋白质、碳水化合物、脂质和核酸等大分子物质等。在本发明的一个实施方式中,所述治疗剂为治疗性大分子。向接受者施用治疗性大分子时可能会引起过强的免疫应答,如抗治疗性大分子特异性抗体的产生。在本发明的一个具体实施方式中,所述治疗性大分子为治疗性蛋白质。
本发明中所述“过强的免疫应答”是指由由暴露于抗原引起的、促进或加重本文中所述疾病、紊乱或病症(或其症状),或者其为本文中所述疾病、紊乱或病症(或其症状)。这样的免疫应答一般对对象的健康具有不良影响或者为对对象之健康的不良影响的症状。过强的免疫应答包括抗原特异性抗体产生、抗原特异性B细胞增殖和/或活性或抗原特异性CD4+T 细胞增殖和/或活性。一般来说,这些过强的免疫应答是治疗性大分子特异性的并且抵消施用所述治疗性大分子所期望的有益效果。
本发明中所述“抗体”以其最广泛的含义使用并且特别覆盖单克隆抗体、多克隆抗体、二聚体、多聚体、多特异性抗体(例如:双特异性抗体)和抗体片段,只要它们表现出所需的生物活性(Miller等(2003)Jour.of Immunology,170:4854-4861)。抗体可以为鼠、人、人源化、嵌合抗体或来源于其它物种。抗体可具有任何类型(例如IgG、IgE、IgM、 IgD及IgA)及类别(例如IgG1、IgG2、IgG3、IgG4、IgA1和IgA2)。
本发明中所述“接受者”为哺乳动物,包括但不限于灵长目动物(如人、猴、猿等)、偶蹄目动物(如猪、羊、牛等)、奇蹄目动物(如马)、啮齿类动物(如老鼠、水豚等)、食肉目动物(包括犬科(如狼、狗)、猫科(如虎、猫)、熊科(如熊猫)等),优选为人。
本发明中所述“移植”是指机体的某种细胞、组织或器官因损伤而导致不可复性的结构及功能损害时,将相应健康细胞、组织或器官植入机体的过程称为细胞、组织或器官的移植(transplantation)。常见的有自体移植、同种异体移植及同基因型移植等。
本发明中所述“药学上可接受的辅料”含义是该成分没有生物活性或其他不良活性的杂质,例如该成分可以纳入公开的药物制剂并给与患者,但不引起显著的不良生物效果或以有害的方式和该制剂中包含的其他成分产生相互作用。
本发明中所述“治疗”包括抑制、延迟、缓和、减弱、限制、减轻或消退疾病、障碍、病症或状态,其发生和/或进程,和/或其症状。
本发明中所述“包含”表示"开放"或"包含性"用语,使得它们包括列举的要素,而且还允许包括额外的、未提及的要素。
本发明中所述“约”通常意指所述值的+/-5%,更通常指所述值的+/-4%,更通常指所述值的+/-3%,更通常指所述值的+/-2%,更通常指所述值的+/-1%,更通常指所述值的 +/-0.5%。
附图说明
图1是实施例2评价针对钥孔血蓝蛋白(KLH)抗体水平的影响实验中G1、G2和G3 三组动物四免效价数据统计结果。
下面将结合本发明实施例,对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有付出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例
实施例中所用的雷帕霉素从武汉远成共创科技有限公司购得,单甲氧基聚乙二醇-谷氨酸二肽、甘氨酸雷帕霉素酯由天津键凯科技有限公司提供,其余为市售试剂。实验动物为Balb/c雌鼠,购自北京华阜康生物科技股份有限公司;免疫原为钥孔血蓝蛋白(KLH),购自美国Sigma公司。
实施例1单甲氧基聚乙二醇(数均分子量20000)-谷氨酸二肽-雷帕霉素结合物(JK1208R)(结构式如下)的制备
将单甲氧基聚乙二醇-谷氨酸二肽(20KDa,5g,0.25mmol)、甘氨酸雷帕霉素酯486mg(0.5mmol)、HOBt(34mg,0.25mmol)和DMAP(61mg,0.5mmol)加到反应瓶中,用二氯甲烷溶解,冰浴冷却,再滴入DCC(155mg,0.75mmol)溶于二氯甲烷的溶液,滴完后自然升到室温,反应过夜。次日将反应液浓缩,残分用异丙醇结晶,得单甲氧基聚乙二醇(20KDa)-谷氨酸二肽-雷帕霉素结合物(JK1208R)4.7g(n约为450)。
实施例2评价针对钥孔血蓝蛋白(KLH)抗体水平的影响
2.1实验动物
种属:小鼠
品系:Balb/c
等级:SPF
繁育单位:北京华阜康生物科技股份有限公司
购入时周龄:5周
购入时体重范围:14-16g
2.2实验动物饲养条件
动物到达后在实验环境饲养3天后方开始实验。动物在SPF级动物房以IVC(独立送风系统)笼具饲养(每笼4只)。每笼动物信息卡注明笼内动物数目,性别,品系,接收日期,给药方案,实验编号,组别以及实验开始日期。所有笼具、垫料、饲料及饮水在使用前均灭菌。笼具、饲料及饮水每周更换两次。饲养环境及光照情况如下:
温度:20-26℃
湿度:40-70%
光照周期:12小时光照,12小时无光照(上午8点开灯~下午8点关灯)
2.3仪器与耗材
2.3.1主要试剂和耗材
所用试剂耗材 | 生产厂家 |
弗氏完全佐剂 | Sigma公司Cat.No F5881 |
弗氏不完全佐剂 | Sigma公司Cat.No F5506 |
2.3.2主要仪器
所用仪器 | 生产厂家 |
DEM-3型自动洗板机 | 北京拓普分析仪器有限责任公司 |
酶标仪 | BIO-RAD 680 |
2.4实验方法及步骤
2.4.1.抗原信息:免疫原:KLH;检测原:KLH
2.4.2试验过程:
G1组(模型组):
动物免疫:
初免:第1天,100ug抗原(免疫原)/只×18只老鼠+同体积弗式完全佐剂,用注射器相互注射的方式形成油包水化合物,皮下多点注射;
二免:第14天,100ug抗原/只×18只老鼠+同体积弗式不完全佐剂,用注射器相互注射的方式形成油包水化合物,皮下多点注射;
三免:第24天,100ug抗原/只×18只老鼠+同体积弗式不完全佐剂,用注射器相互注射的方式形成油包水化合物,皮下多点注射;
尾血检测:第28-29天,尾静脉采集约20ul尾血,RT30min,5000转离心5min,弃血细胞沉淀,吸取血清,用于Elisa检测效价;
四免:第34天,100ug抗原/只×18只老鼠+同体积弗式不完全佐剂,用注射器相互注射的方式形成油包水化合物,皮下多点注射;
G2组(IV组):同G1组进行对照免疫,同时,在第0天和第7天分别静脉注射JK1208R(实施例1制备)620mg。
G3组(PO组):同G1组进行对照免疫,同时在第0天和第7天分别口服雷帕霉素52 μg。
尾血检测:第40-41天,尾静脉采集约20ul尾血,RT30min,5000转离心5min,弃血细胞沉淀,吸取血清,用于ELISA检测效价。
2.4.3效价检测:(酶联免疫吸附法(ELISA))
包被:10ug抗原(检测原)+10ml包被液(1.6gNaCO3+2.92gNaHCO3+100ml去离子水),混匀,100ul/孔铺Elisa板,37℃孵育2h或者4℃过夜;
封闭:包被好的板子吸弃抗原包被液,直接加入封闭液(5%脱脂奶粉+包被液)150ul/ 孔,37℃下处理2h后洗板3次,去离子水洗即可,4℃暂存;
检测:血清1:1000 1×PBS,混匀,吸150ul稀释液加入第一个孔,第2-8孔均加入100ul1×PBS,从第一个孔吸50ul液体加入第二孔,吸吹10次后吸取50ul到第三孔,吸吹10次后吸50ul到第四孔,依次吸吹到第7孔后吸取50ul丢弃,第八孔作为阴性对照; 37℃孵育1h后去离子水洗3次,加二抗(羊抗鼠IgG-HRP 1:10000 1×PBS)100ul/孔, 37℃孵育30min后去离子水洗3次,加入显色液(依照试剂盒说明书使用),100ul/孔, 37℃10min后终止(2M硫酸30ul/孔),酶标仪检测OD值。
2.5实验结果:
G1、G2和G3三组动物四免效价数据统计结果如表1和附图1所示。
表1 PO组和IV组对KLH抗体产生的影响
注:与模型组比较*P<0.05,**P<0.01,***P<0.001
由结果可知,三免后PO组和IV组与免疫模型组相比较,在1:3K时数据经过统计分析,IV组和免疫模型组有显著性差异,而PO组数据无显著差异。四免后PO组和IV组与免疫模型组相比较,在1:1K和1:3K时数据经过统计分析,IV组和免疫模型组均有显著性差异,而PO组数据无显著差异。说明IV组四免后能显著降低KLH抗体的产生。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换等,均应包含在本发明的保护范围之内。
Claims (18)
1.一种聚乙二醇与雷帕霉素的结合物在制备用于减少免疫应答的药物中的用途。
2.如权利要求1所述的用途,其特征在于,所述聚乙二醇与雷帕霉素的结合物具有通式Ⅰ所示结构:
PEG-X-D
(Ⅰ)
其中,
PEG为聚乙二醇残基,
D为雷帕霉素或其衍生物残基,
X为PEG和D之间的连接基团。
3.如权利要求2所述的用途,其特征在于,所述结合物中,所述X具有如下结构:-X1-X2-X3-,其中,X1和X3独立地选自:-(CR1R2)a-、-(CH2)aNH-、-(CH2)aNHCO-、-(CH2)aCONH-、-(CH2)aCO-、-(CH2)aCOO-和-(CH2)aO-中的一种或多种的组合,X2选自:环烷基、芳基、杂环基、-A-和-Op-,R1和R2独立地选自:-H、C1-6的烷基、-OR'、-NHR'、-N(R')2、-CN、-F、-Cl、-Br、-I、-COR'、-COOR'、-OCOR'、-CONHR'和-CON(R')2中的一种或两种以上的组合,R'选自:-H、C1-6的烷基、-F、-Cl、-Br和-I,
a为0-10的整数,
-A-为氨基酸残基,
-Op-为寡肽残基,具有如下结构:
其中,m为1、2、3或4,
A1选自:天冬氨酸、谷氨酸和赖氨酸的残基,
A2和A3为相同或不同的氨基酸残基。
4.如权利要求3所述的用途,其特征在于,所述结合物具有如下结构:
5.如权利要求1-4任一项所述的用途,其特征在于,所述的免疫应答是由外源免疫原引起的过强的免疫应答,所述的外源免疫原选自:治疗剂、移植物、人工抗原载体和毒素。
6.如权利要求5所述的用途,其特征在于,所述治疗剂为治疗性蛋白质,选自:细胞因子、人血红蛋白、血液因子或凝血因子、血管内皮生长因子抗体拮抗剂、激素、抗体、酶及辅酶中的一种或多种。
7.如权利要求6所述的用途,其特征在于,所述血液因子或凝血因子选自:因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、重组凝血因子、冯·维勒布兰德因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤溶酶、组织纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌促凝物质和阿法依伯汀中的一种或多种。
8.如权利要求6所述的用途,其特征在于,所述抗体包括:单克隆抗体、多克隆抗体、二聚体、多聚体、双特异性抗体、多特异性抗体和抗体片段。
9.如权利要求6所述的用途,其特征在于,所述酶及辅酶选自:伊米苷酶、α-半乳糖苷酶A、阿加糖酶β、酸性α-葡糖苷酶、重组阿葡糖苷酶α、α-葡糖苷酶、芳基硫酸酯酶、拉罗尼酶、ALDURAZYME、艾杜硫酶、ELAPRASE、加硫酶、聚乙二醇化重组尿酸酶、聚乙二醇化重组假丝酵母尿酸酶和门冬酰胺酶中的一种或多种。
10.如权利要求5所述的用途,其特征在于,所述人工抗原载体为蛋白质载体,选自:钥孔血蓝蛋白、牛血清蛋白、人血清白蛋白和卵清蛋白。
11.如权利要求10所述的用途,其特征在于,所述人工抗原载体为钥孔血蓝蛋白。
12.一种PEG与雷帕霉素的结合物在制备增强第一药物治疗效果的药物中的用途,所述的第一药物选自细胞因子、人血红蛋白、血液因子或凝血因子、血管内皮生长因子抗体拮抗剂、激素、抗体、酶及辅酶类药物中的至少一种。
13.如权利要求12所述的用途,其特征在于,所述PEG与雷帕霉素的结合物具有通式Ⅰ所示结构:
PEG-X-D
(Ⅰ)
其中,
PEG为聚乙二醇残基,
D为雷帕霉素或其衍生物残基,
X为PEG和D之间的连接基团。
14.如权利要求12-13任一项所述的用途,其特征在于,所述血液因子或凝血因子选自:因子I、因子II、组织因子、因子V、因子VII、因子VIII、因子IX、因子X、因子Xa、因子XII、因子XIII、重组凝血因子、冯·维勒布兰德因子、前激肽释放酶、高分子量激肽原、纤连蛋白、抗凝血酶III、肝素辅因子II、蛋白C、蛋白S、蛋白Z、蛋白Z相关蛋白酶抑制剂(ZPI)、纤溶酶原、α2-抗纤溶酶、组织纤溶酶原激活物(tPA)、尿激酶、纤溶酶原激活物抑制剂-1(PAI1)、纤溶酶原激活物抑制剂-2(PAI2)、癌促凝物质和阿法依伯汀中的一种或多种;优选为因子VIII。
15.如权利要求12-13任一项所述的用途,其特征在于,所述抗体包括:单克隆抗体、多克隆抗体、二聚体、多聚体、双特异性抗体、多特异性抗体和抗体片段;优选地,所述单克隆抗体为阿达木单抗。
16.如权利要求12-13任一项所述的用途,其特征在于,所述酶及辅酶选自:伊米苷酶、α-半乳糖苷酶A、阿加糖酶β、酸性α-葡糖苷酶、重组阿葡糖苷酶α、α-葡糖苷酶、芳基硫酸酯酶、拉罗尼酶、ALDURAZYME、艾杜硫酶、ELAPRASE、加硫酶、聚乙二醇化重组尿酸酶、聚乙二醇化重组假丝酵母尿酸酶和门冬酰胺酶中的一种或多种;优选为α-半乳糖苷酶A、酸性α-葡糖苷酶、聚乙二醇化重组尿酸酶、聚乙二醇化重组假丝酵母尿酸酶或门冬酰胺酶。
17.如权利要求12-16任一项所述的用途,其特征在于,所述的第一药物用于治疗肿瘤、血液疾病、感染性疾病、免疫系统疾病、遗传性疾病或代谢病。
18.如权利要求17所述的用途,其特征在于,所述的肿瘤选自:肺癌、肾癌、黑色素瘤、肝癌头颈癌、皮肤癌、鳞状细胞癌、卵巢癌、骨癌、结直肠癌、膀胱癌、胃癌、胰腺癌、前列腺癌、霍奇金淋巴瘤、滤泡性淋巴瘤、慢性或急性白血病、间皮瘤、胰腺癌、乳腺癌、多发性骨髓瘤和其他实体瘤;
所述的血液疾病选自血友病;
所述的感染性疾病选自:HIV病毒感染、肝炎病毒感染、疱疹病毒感染和流感病毒感染;
所述免疫系统疾病选自:红斑狼疮、类风湿关节炎、强直性脊柱炎、重症肌无力、多发性硬化症、自身免疫性溶血性贫血、自身免疫性肝炎、硬皮病、结节性多动脉炎和Wegener肉芽肿病;
所述的遗传性疾病选自:法布里病、庞培氏病、溶酶体积存疾病、遗传性肌肉疾病和遗传代谢疾病;
所述的代谢病选自:氨基酸代谢紊乱、糖原贮积病I、吸收不良疾病、寡醣酶缺乏症、果糖代谢障碍、半乳糖代谢障碍、半乳糖血症、碳水化合物利用紊乱、低血糖症、丙酮酸盐代谢紊乱、低脂血症、低脂蛋白血症、高脂血症、高脂蛋白血症、肉毒碱或肉毒碱酰基转移酶缺乏症、卟啉代谢紊乱、卟啉、嘌呤代谢紊乱、溶酶体病、神经及神经系统代谢疾病、硫酸脑苷脂病、脑白质病和莱施-奈恩综合征。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810273306 | 2018-03-29 | ||
CN2018102733062 | 2018-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110314236A true CN110314236A (zh) | 2019-10-11 |
Family
ID=68060927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910241970.3A Pending CN110314236A (zh) | 2018-03-29 | 2019-03-28 | 聚乙二醇与雷帕霉素的结合物及其用途 |
Country Status (3)
Country | Link |
---|---|
US (2) | US20210023232A1 (zh) |
CN (1) | CN110314236A (zh) |
WO (1) | WO2019184993A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022206796A1 (zh) * | 2021-04-02 | 2022-10-06 | 杭州宜生医药科技发展有限公司 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104448295A (zh) * | 2013-12-02 | 2015-03-25 | 北京键凯科技有限公司 | 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物 |
CN105307641A (zh) * | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60136200D1 (de) * | 2000-09-19 | 2008-11-27 | Wyeth Corp | Wasserlösliche rapamycin-ester |
US7605257B2 (en) * | 2006-03-07 | 2009-10-20 | Wyeth | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
-
2019
- 2019-03-28 CN CN201910241970.3A patent/CN110314236A/zh active Pending
- 2019-03-28 US US17/042,887 patent/US20210023232A1/en not_active Abandoned
- 2019-03-28 WO PCT/CN2019/080194 patent/WO2019184993A1/zh active Application Filing
-
2022
- 2022-09-01 US US17/901,108 patent/US20230036997A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105307641A (zh) * | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
CN104448295A (zh) * | 2013-12-02 | 2015-03-25 | 北京键凯科技有限公司 | 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022206796A1 (zh) * | 2021-04-02 | 2022-10-06 | 杭州宜生医药科技发展有限公司 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
CN115160559A (zh) * | 2021-04-02 | 2022-10-11 | 杭州宜生医药科技发展有限公司 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
CN115160559B (zh) * | 2021-04-02 | 2024-02-02 | 杭州宜生医药科技发展有限公司 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
US20210023232A1 (en) | 2021-01-28 |
US20230036997A1 (en) | 2023-02-02 |
WO2019184993A1 (zh) | 2019-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102596221B (zh) | 病理tau蛋白的免疫靶向 | |
CN103501820B (zh) | 用于效应性t细胞的抗原特异性缺失的致耐受性合成纳米载体 | |
CN105055306B (zh) | 包含抗体和防腐剂的稳定的多剂量组合物 | |
KR101759694B1 (ko) | 아미노산을 함유하는 단백질 제제 | |
CN110251675A (zh) | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 | |
CN109689097A (zh) | 包含具有fc结合能力的融合蛋白的细胞外囊泡 | |
CN103037899A (zh) | 包含稳定抗体的组合物 | |
CN107532156A (zh) | 半胱氨酸蛋白酶 | |
CN104519911A (zh) | 抗体和糖苷内切酶的联合治疗应用 | |
CN105263491A (zh) | 非免疫抑制性抗原特异性免疫治疗剂的重复施用 | |
US20210386680A1 (en) | Selectively cleavable therapeutic nanoparticles | |
US20230036997A1 (en) | Combination of polyethylene glycol and rapamycin and use thereof | |
US11697670B2 (en) | Methods for purifying antibodies having reduced high molecular weight aggregates | |
US20170056504A1 (en) | Method of extending half-life of crystaline antibodies | |
CN109982716A (zh) | 在加工过程中稳定生物制药药物产品的新方法 | |
US20220249681A1 (en) | Dual drug antibody-drug conjugates | |
RU2817008C1 (ru) | Аффимеры, связывающиеся с неонатальным fc рецептором | |
WO2019105444A1 (zh) | 蛋白质的生产方法 | |
CN105859837B (zh) | 胆固醇酯转运蛋白抗原肽和融合蛋白以及其组合物和应用 | |
JP2016504344A (ja) | 高温デッドエンド抗体ろ過 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191011 |